PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml.
Nantia SolomonidouDaphnie GermanouIosif StrouthosEfstratios KaragiannisAndrea FarolfiStefan A KoerberJuergen DebusJan C PeekenMarco E VogelAlexis VrachimisSimon K B SpohnMohamed ShelanDaniel AebersoldAnca-Ligia GrosuFrancesco CeciStephanie G C KroezeMatthias GuckenbergerStefano FantiClaus BelkaGeorge HrubyS ScharlThomas WiegelPeter BartensteinChristoph HenkenberensLouise EmmettNina Sophie Schmidt-HegemannKonstantinos FerentinosConstantinos ZamboglouPublished in: European journal of nuclear medicine and molecular imaging (2023)
This multicenter analysis suggests that implementation of PSMA-PET/CT imaging for sRT guidance might be of benefit for patients with very low PSA levels after surgery due to promising BRFS rates and a low number of relapses within the sRT field.